Biotechnology: delivering on the promise.

The research and development of innovative new therapies are expensive and risky processes, and companies require substantial resources if they are to translate basic science into modern biomedical products. When resources are limited, as in the current economic climate, biotechnology start-up companies are often among the first casualties in the fight for assets. Policy-makers can play an important role in bolstering these important innovators.